Products

Our Technology

Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to:

  1. Match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES);
  2. Come in a range of sizes and lengths
  3. Provide equivalent mechanical performance (radial strength) to the best-in-classDrug Eluting Stent (DES) products
  4. Generate fewer clinical adverse events than current Drug Eluting Stent (DES)
  5. Be resorbed within 24 months leaving nothing behind which might complicate future revascularisations
  6. Overcome the high in-stent late lumen loss (narrowing of the vessel once the stent has dissolved) which has limited the adoption of first generation products

Accomplishing the above will support the positioning of a premium priced BRS product which could claim significant stent market share with higher margins than existing Bare Metal Stent (BMS) and Drug Eluting Stent (DES);

ArterioSorb™

STENT DESIGN
Stent Design
Figure 1

ArterioSorb™ is produced from the FDA approved polymer, PLLA, which is already universally approved for use in cardiovascular stents, sutures and orthopaedic applications. ArterioSorb™ is a tubular stent with closed-cell (with connectors for strength) and open-cell (with fewer connectors for flexibility) modules and increasing cell size as one moves away from the centre: The smaller cells at the centre provide the greatest radial support and higher drug delivery, where the stenosis is most severe, while the larger cells provide greater flexibility for ease of implantation.

The design also allows a thinner strut thickness, which is conventionally associated with lower incidence of [thrombosis and restenosis]. An example of a prototype open-cell design is illustrated in Figure 1.

The team at Arterius believe that the bioresorbable scaffold shown above has a competitive product profile and can be positioned for success both in the EU and in other large commercial markets. In particular, the precedents set in the adoption of DES technology suggest that if future BRS trials, including Arterius’s ArterioSorb™, can provide data evidencing the prevention of late in-stent restenosis (and need for repeat procedures) and late-stent thrombosis, which are considered amongst the most pressing unmet needs in interventional cardiology, then these technologies could claim a large proportion of the $8.1bn market.

RADIAL STRENGTH (LOW LATE LUMEN LOSS)
DRUG COATING AND ELUTION PROFILE
COMPLETE ABSORPTION
EASE OF USE
POLYMER PROCESSING TECHNOLOGY
PRE-CLINICAL ACUTE STUDY EVALUATION